Free Trial
NASDAQ:VERA

Vera Therapeutics (VERA) Stock Price, News & Analysis

Vera Therapeutics logo
$22.54 +0.20 (+0.87%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Vera Therapeutics Stock (NASDAQ:VERA)

Key Stats

Today's Range
$22.13
$22.66
50-Day Range
$18.86
$29.96
52-Week Range
$18.53
$51.61
Volume
250,687 shs
Average Volume
747,531 shs
Market Capitalization
$1.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.67
Consensus Rating
Buy

Company Overview

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

VERA MarketRank™: 

Vera Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 486th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Vera Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Vera Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.89) to ($3.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vera Therapeutics is -8.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vera Therapeutics is -8.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vera Therapeutics has a P/B Ratio of 11.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Vera Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    13.36% of the float of Vera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vera Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Vera Therapeutics has recently decreased by 9.79%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Vera Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Vera Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.36% of the float of Vera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vera Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Vera Therapeutics has recently decreased by 9.79%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Vera Therapeutics has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Vera Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    2 people have searched for VERA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vera Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.30% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vera Therapeutics' insider trading history.
Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERA Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…
Guggenheim Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
See More Headlines

VERA Stock Analysis - Frequently Asked Questions

Vera Therapeutics' stock was trading at $42.29 on January 1st, 2025. Since then, VERA shares have decreased by 47.0% and is now trading at $22.4250.
View the best growth stocks for 2025 here
.

Vera Therapeutics, Inc. (NASDAQ:VERA) released its quarterly earnings results on Wednesday, February, 26th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.11.

Vera Therapeutics (VERA) raised $66 million in an IPO on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO.

Top institutional shareholders of Vera Therapeutics include Rhumbline Advisers (0.10%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Commodore Capital Lp, Sofinnova Venture Partners X,, Carlyle Group Inc, Maha Katabi, Marshall Fordyce, Beth C Seidenberg, Sean Grant, Joseph R Young, Joanne Curley and Celia Lin.
View institutional ownership trends
.

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
2/26/2025
Today
4/24/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VERA
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$64.67
High Stock Price Target
$107.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+188.4%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-95,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.94 per share
Price / Book
11.56

Miscellaneous

Free Float
49,582,000
Market Cap
$1.43 billion
Optionable
Optionable
Beta
1.28
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:VERA) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners